Despite the price drops, the drugs remain costly. Novo Nordisk cut the price of Wegovy by 23 percent for cash payments from ...

Laura Davisson is an obesity medicine doctor and professor at West Virginia University, but a growing part of her job is not ...

Novo Nordisk is rapidly ceding market share to Eli Lilly. And the paradigm shift is showing up in Novo Nordisk stock.

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Researchers find tirzepatide more effective than semaglutide for weight loss in a 72-week trial, with significant reductions in body weight and waist circumference.

Drugmakers are offering the blockbuster medications at steep discounts to people willing to pay out of pocket.

Zepbound is a weekly injectable prescription weight loss medication with the active ingredient tirzepatide. It’s a GLP-1 agonist drug that slows stomach emptying, meaning you feel fuller for ...

Shares in Eli Lilly have weakened after CVS Health, one of the largest pharmacy benefit managers (PBMs) in the US, said it would no longer cover its obesity therapy Zepbound. The shares closed ...

Telehealth company Ro will offer single-dose vials of Eli Lilly's obesity therapy Zepbound in an expansion of the ways patients with a prescription can access the drug. The agreement means Ro has ...

For example, Medicare and Medicaid generally do not cover ... Another drug called Zepbound contains the same active ingredient as Mounjaro and is FDA approved for weight loss.